logo
  Join        Login             Stock Quote

FDA OKs Expanded Use Of Bayer/Onyx Drug For Rare Gastrointestinal Tumor

 February 25, 2013 02:51 PM
 


(By Balachander) The U.S. Food and Drug Administration (FDA) has approved the expanded use of Bayer AG's drug Stivarga to treat a rare type of gastrointestinal tract cancer.

Stivarga, which was approved in September 2012 to treat colorectal cancer, is the third drug cleared by the U.S. health regulators to treat gastrointestinal stromal tumors (GIST).

Germany-based Bayer and South San Francisco, California-based Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) co-promote Stivarga - known as regorafenib - in the United States.

The FDA on Monday approved Stivarga for patients whose GIST cannot be surgically removed and no longer respond to other FDA-approved treatments Novartis' (NVS) Gleevec and Pfizer's (PFE) Sutent.

[Related -Pfizer Inc. (PFE) Q3 Earnings Preview: What To Watch?]

GIST is a tumor in which cancerous cells form in the tissues of the gastrointestinal tract, part of the body's digestive system. According to the National Cancer Institute, an estimated 3,300 to 6,000 new cases of GIST occur yearly in the United States, most often in older adults.

According to the FDA, clincial study results showed patients taking Stivarga had a delay in tumor growth that was, on average, 3.9 months later than patients who were given a placebo.

[Related -Jobs Growth Tepid At Best]

The most common side effects reported in patients treated with Stivarga were weight loss, stomach pain, rash, fever, hand-foot syndrome, diarrhea, loss of appetite, high blood pressure and nausea.

Onyx shares inched 0.13 percent higher to trade at $78.40 at 2.38 pm ET on Monday.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageInitial Jobless Claims Rose Unexpectedly

Claims unexpectedly rose in the latest report through last weekend to breach 300,000 for the first time read on...

article imageAll Quiet on the Record High Front

What can we glean from the media’s lack of attention to the market’s recent record read on...

article imageThe Chip Maker Short Sellers Should Be Watching

Investing in semiconductor stocks is always tricky. Industry cycles can lead to bumps in the road for the read on...

article imageChicago Fed: US Economic Growth Slowed In October

The pace of US growth slowed more than expected in October, according to this morning’s update of the read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.